Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III, Global, Multicentre, Open Label Clinical Trial Comparing Venetoclax Azacytidine and Quizartinib Versus Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia Patients Unelegible for Standard Induction Chemotherapy

NCT07478991 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT07478991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07478991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III, Global, Multicentre, Open Label Clinical Trial Comparing Venetoclax Azacytidine and Quizartinib Versus Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia Patients Unelegible for Standard Induction Chemotherapy
Lead sponsor
PETHEMA Foundation
Phase
Phase 3
Overall status
Recruiting
Start date
July 2, 2026
Completion date
April 30, 2030
Enrollment
376 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, adult